Therapeutic uses of MAbs directed against CD20

Research output: Contribution to journalArticle

4 Scopus citations


Background: There are two main classes of Abs directed against the CD20 Ag that have been developed for therapeutic intent: Unconjugated and radiolabeled Abs. Methods: The clinical results available from the large clinical trials utilizing both the unconjugated and radiolabelled Abs are summarized in this article. Discussion: Both of these classes of agents have shown promise in clinical trials both alone and in conjunction with conventional chemotherapy or high-dose chemotherapy and transplantation. Ongoing research with these agents will provide further evidence of the place in clinical practice for these agents.

Original languageEnglish (US)
Pages (from-to)455-462
Number of pages8
Issue number6
StatePublished - Jan 1 2000



  • Bexxar
  • Monoclonal antibodies
  • Rituximab
  • Zevalin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Genetics(clinical)
  • Cell Biology
  • Cancer Research
  • Transplantation

Cite this